Salus Scientific Secures $10.1 Million in Series A Funding

Salus Scientific Secures $10.1 Million in Series A Funding

Salus Scientific, based in Mount Pleasant, South Carolina, has successfully closed a Series A funding round, raising $10.1 million. The company, which is developing an occupational wellness platform aimed at enhancing safety for medical professionals involved in fluoroscopy-guided procedures, surpassed its initial funding target of $8 million due to strong investor interest.

Funding Details

The Series A round was oversubscribed, indicating robust support from investors, though specific investor names have not been disclosed. The company plans to use the funds to scale its commercial operations and enhance its clinical infrastructure.

Strategic Use of Funds

The newly acquired capital will be directed towards expanding Salus Scientific's production capabilities and clinical infrastructure. This investment will also support the company's efforts to prepare for larger-scale commercialization and a significant revenue increase.

Leadership Insights

Todd Flohr, the Founder and CEO of Salus Scientific, commented on the successful funding round: "We are pleased to have closed our Series A above target and ahead of schedule. The round's oversubscription is a direct endorsement of both our commercial thesis and our execution discipline."

Salus Scientific's commitment to advancing occupational wellness in procedural medicine is gaining traction, as evidenced by the successful Series A funding. The company is now well-positioned to enhance its market presence and expand its innovative solutions for healthcare professionals.